{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Recurrent+Non-Small+Lung+Cell+Cancer", "query": { "condition": "Recurrent Non-Small Lung Cell Cancer" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 621, "total_pages": 63, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Recurrent+Non-Small+Lung+Cell+Cancer&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-07-23T01:53:47.777Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06712810", "title": "Q702 for the Treatment of Patients With Hematologic Malignancies", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Hematopoietic and Lymphatic System Neoplasm", "Histiocytic Sarcoma", "Malignant Histiocytosis", "Peripheral T-Cell Lymphoma, Not Otherwise Specified", "Primary Cutaneous T-Cell Non-Hodgkin Lymphoma", "Recurrent Chronic Lymphocytic Leukemia", "Recurrent Chronic Myelomonocytic Leukemia", "Recurrent Follicular Lymphoma", "Recurrent Langerhans Cell Histiocytosis", "Recurrent Lymphoplasmacytic Lymphoma", "Recurrent Myelodysplastic Syndrome", "Recurrent Myelofibrosis", "Recurrent Small Lymphocytic Lymphoma", "Recurrent Waldenstrom Macroglobulinemia", "Refractory Chronic Lymphocytic Leukemia", "Refractory Chronic Myelomonocytic Leukemia", "Refractory Erdheim-Chester Disease", "Refractory Follicular Lymphoma", "Refractory Langerhans Cell Histiocytosis", "Refractory Lymphoplasmacytic Lymphoma", "Refractory Myelodysplastic Syndrome", "Refractory Myelofibrosis", "Refractory Small Lymphocytic Lymphoma", "Refractory Waldenstrom Macroglobulinemia", "Rosai-Dorfman-Destombes Disease", "Primary Central Nervous System Lymphoma", "Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm", "Recurrent Erdheim-Chester Disease", "Recurrent Fibroblastic Reticular Cell Sarcoma", "Recurrent Histiocytic Sarcoma", "Recurrent Interdigitating Dendritic Cell Sarcoma", "Recurrent Rosai-Dorfman-Destombes Disease", "Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm", "Refractory Fibroblastic Reticular Cell Sarcoma", "Refractory Histiocytic Sarcoma", "Refractory Interdigitating Dendritic Cell Sarcoma", "Refractory Rosai-Dorfman-Destombes Disease" ], "interventions": [ { "name": "Axl/Mer/CSF1R Inhibitor Q702", "type": "DRUG" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Bone Marrow Aspiration", "type": "PROCEDURE" }, { "name": "Bone Marrow Biopsy", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Survey Administration", "type": "OTHER" } ], "intervention_types": [ "DRUG", "PROCEDURE", "OTHER" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 46, "start_date": "2025-08-27", "completion_date": "2030-09-15", "has_results": false, "last_update_posted_date": "2025-10-10", "last_synced_at": "2026-07-23T01:53:47.777Z", "location_count": 2, "location_summary": "Scottsdale, Arizona • Rochester, Minnesota", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT06712810" }, { "nct_id": "NCT03625323", "title": "Combination Study With Soluble LAG-3 Fusion Protein Eftilagimod Alpha (IMP321) and Pembrolizumab in Patients With Previously Untreated Unresectable or Metastatic NSCLC, or Recurrent PD-X Refractory NSCLC or With Recurrent or Metastatic HNSCC", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "NSCLC", "HNSCC" ], "interventions": [ { "name": "eftilagimod alpha", "type": "DRUG" }, { "name": "pembrolizumab (KEYTRUDA®)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Immutep S.A.S.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 187, "start_date": "2019-02-21", "completion_date": "2024-11-25", "has_results": true, "last_update_posted_date": "2026-04-22", "last_synced_at": "2026-07-23T01:53:47.777Z", "location_count": 1, "location_summary": "Huston, Texas", "locations": [ { "city": "Huston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03625323" }, { "nct_id": "NCT00356941", "title": "Oxaliplatin, Docetaxel, and Radiation Therapy in Treating Patients With Unresectable Stage II/III or Recurrent NSCLC", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lung Cancer" ], "interventions": [ { "name": "docetaxel", "type": "DRUG" }, { "name": "oxaliplatin", "type": "DRUG" }, { "name": "radiation therapy", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "Masonic Cancer Center, University of Minnesota", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 4, "start_date": "2006-04", "completion_date": "2007-05", "has_results": false, "last_update_posted_date": "2017-11-29", "last_synced_at": "2026-07-23T01:53:47.777Z", "location_count": 1, "location_summary": "Minneapolis, Minnesota", "locations": [ { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT00356941" }, { "nct_id": "NCT00293280", "title": "Lomustine in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lung Cancer" ], "interventions": [ { "name": "lomustine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 42, "start_date": "2005-07", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-05-06", "last_synced_at": "2026-07-23T01:53:47.777Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00293280" }, { "nct_id": "NCT00287989", "title": "Erlotinib, Paclitaxel, and Carboplatin in Treating Patients With Stage III, Stage IV, or Recurrent Non-Small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lung Cancer" ], "interventions": [ { "name": "Carboplatin", "type": "DRUG" }, { "name": "erlotinib hydrochloride", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 86, "start_date": "2004-11", "completion_date": "2009-05", "has_results": true, "last_update_posted_date": "2018-12-06", "last_synced_at": "2026-07-23T01:53:47.777Z", "location_count": 2, "location_summary": "Baltimore, Maryland • New York, New York", "locations": [ { "city": "Baltimore", "state": "Maryland" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00287989" }, { "nct_id": "NCT04340882", "title": "Phase 2 DoceRamPem for Patients With Metastatic or Recurrent NSCLC Who Progressed on Platinum-Doublet and PD-1/PD-L1 Blockade", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Non-Small Lung Cell Cancer", "Recurrent Non-Small Lung Cell Cancer", "Stage IV Lung Cancer AJCC v8", "Stage IVA Lung Cancer AJCC v8", "Stage IVB Lung Cancer AJCC v8" ], "interventions": [ { "name": "Docetaxel", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Ramucirumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Emory University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2020-06-05", "completion_date": "2030-09-30", "has_results": false, "last_update_posted_date": "2026-01-30", "last_synced_at": "2026-07-23T01:53:47.777Z", "location_count": 2, "location_summary": "Atlanta, Georgia", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT04340882" }, { "nct_id": "NCT05891197", "title": "A Biomarker Screening Protocol for Participants With Solid Tumors", "overall_status": "TERMINATED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Triple Negative Breast Cancer", "Non-small Cell Lung Cancer", "Non Small Cell Lung Cancer", "Non Small Cell Lung Cancer Metastatic", "Non-Small Cell Carcinoma of Lung, TNM Stage 4", "Advanced Breast Cancer", "Advanced Lung Carcinoma", "NSCLC", "NSCLC, Recurrent", "NSCLC Stage IV", "Relapsed Cancer", "Relapse/Recurrence", "Recurrent Breast Cancer", "Recurrent NSCLC", "Platinum-resistant Ovarian Cancer", "Ovarian Cancer", "Primary Peritoneal Carcinoma", "Fallopian Tube Cancer", "Endometrial Cancer", "Endometrioid Tumor", "High Grade Serous Carcinoma", "Ovarian Epithelial Cancer" ], "interventions": [], "intervention_types": [], "sponsor": "Lyell Immunopharma, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 10, "start_date": "2023-05-19", "completion_date": "2025-02-05", "has_results": false, "last_update_posted_date": "2025-07-01", "last_synced_at": "2026-07-23T01:53:47.777Z", "location_count": 1, "location_summary": "Rocky Mount, North Carolina", "locations": [ { "city": "Rocky Mount", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT05891197" }, { "nct_id": "NCT02955290", "title": "CIMAvax Vaccine, Nivolumab, and Pembrolizumab in Treating Patients With Advanced Non-small Cell Lung Cancer or Squamous Head and Neck Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Head and Neck Squamous Cell Carcinoma", "Lung Non-Small Cell Carcinoma", "Metastatic Lung Non-Small Cell Carcinoma", "PD-L1 Positive", "Recurrent Head and Neck Squamous Cell Carcinoma", "Stage III Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8", "Stage III Lung Cancer AJCC v8", "Stage IIIA Lung Cancer AJCC v8", "Stage IIIB Lung Cancer AJCC v8", "Stage IIIC Lung Cancer AJCC v8", "Stage IV Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8", "Stage IV Lung Cancer AJCC v8", "Stage IVA Lung Cancer AJCC v8", "Stage IVB Lung Cancer AJCC v8", "Unresectable Lung Non-Small Cell Carcinoma", "Advanced Squamous Non-Small Cell Lung Carcinoma" ], "interventions": [ { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Pembrolizumab", "type": "BIOLOGICAL" }, { "name": "Recombinant Human EGF-rP64K/Montanide ISA 51 Vaccine", "type": "BIOLOGICAL" } ], "intervention_types": [ "OTHER", "BIOLOGICAL" ], "sponsor": "Roswell Park Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 51, "start_date": "2016-12-22", "completion_date": "2027-12-09", "has_results": false, "last_update_posted_date": "2025-11-10", "last_synced_at": "2026-07-23T01:53:47.777Z", "location_count": 5, "location_summary": "Indianapolis, Indiana • Buffalo, New York • Roslyn, New York + 2 more", "locations": [ { "city": "Indianapolis", "state": "Indiana" }, { "city": "Buffalo", "state": "New York" }, { "city": "Roslyn", "state": "New York" }, { "city": "West Islip", "state": "New York" }, { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT02955290" }, { "nct_id": "NCT00036790", "title": "Motexafin Gadolinium and Doxorubicin in Treating Patients With Advanced Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Breast Cancer", "Chronic Myeloproliferative Disorders", "Colorectal Cancer", "Head and Neck Cancer", "Leukemia", "Lung Cancer", "Lymphoma", "Multiple Myeloma and Plasma Cell Neoplasm", "Myelodysplastic/Myeloproliferative Diseases", "Prostate Cancer", "Small Intestine Cancer", "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "doxorubicin hydrochloride", "type": "DRUG" }, { "name": "motexafin gadolinium", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Wisconsin, Madison", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": null, "start_date": "2002-02", "completion_date": null, "has_results": false, "last_update_posted_date": "2019-12-17", "last_synced_at": "2026-07-23T01:53:47.777Z", "location_count": 2, "location_summary": "Pittsburgh, Pennsylvania • Madison, Wisconsin", "locations": [ { "city": "Pittsburgh", "state": "Pennsylvania" }, { "city": "Madison", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT00036790" }, { "nct_id": "NCT03175224", "title": "APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Solid Tumors", "Advanced Cancer", "Renal Cancer", "Gastric Cancer", "Gastroesophageal Junction Adenocarcinoma", "NSCLC", "Lung Cancer", "Brain Tumor", "Glioblastoma Multiforme", "EGFR Gene Mutation", "MET Amplification", "HGF", "Thyroid Cancer", "Pancreatic Cancer", "Colon Cancer", "MET Alteration", "MET Fusion", "Exon 14 Skipping" ], "interventions": [ { "name": "APL-101 Oral Capsules", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Apollomics Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 497, "start_date": "2017-09-27", "completion_date": "2026-11-30", "has_results": false, "last_update_posted_date": "2025-06-27", "last_synced_at": "2026-07-23T01:53:47.777Z", "location_count": 6, "location_summary": "Los Angeles, California • Tampa, Florida • Boston, Massachusetts + 3 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Tampa", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Chapel Hill", "state": "North Carolina" }, { "city": "Hershey", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT03175224" } ] }